奥扎格雷钠联合低分子肝素钙对短暂性脑缺血发作的疗效及内皮素和组织因子促凝活性的影响  

The Ozagrel Influence of Sodium Combined Low Molecular Heparin Calcium's Treatment on Transient Ischemic Attack to ET-1 and Whole Blood Tissue Factor Coagulant Activity

作　　者：郭梅[1] 雷蕾[2] 潘国雄[1] 赵瑛[1] 易蕾[1] 陈琦[3] 

机构地区：[1]武汉科技大学附属天佑医院药品采购与调剂科,武汉430064 [2]武汉科技大学附属天佑医院神经内科,武汉430064 [3]武汉科技大学附属天佑医院检验科,武汉430064

出　　处：《微循环学杂志》2014年第4期26-28,34,共4页Chinese Journal of Microcirculation

摘　　要：目的:回顾性分析奥扎格雷钠联合低分子肝素钙对短暂性脑缺血发作(TIA)患者血浆内皮素-1(ET-1)及全血组织因子促凝活性(TF-PCA)的影响。方法:选取108例经临床确诊的TIA患者,按随机数字表法分为奥扎格雷钠联合低分子肝素钙治疗组(观察组,n=54)和低分子肝素钙治疗对照组(治疗组,n=54),两组均给予降压、降脂、控制血糖等常规措施,另选同期体检健康者为对照组(n=56)。1个疗程后(7天)观察两组TIA患者临床疗效及不良反应,并分析治疗前后两组血浆ET-1及全血TF-PCA水平变化。结果:观察组的治愈率和总有效率均明显高于治疗组(70.37%vs 46.30%,94.44%vs 72.22%,P均<0.05)。治疗前,两组TIA患者ET-1及TFPCA水平无明显差异,但均显著高于对照组(P<0.01);治疗后,两组患者ET-1及TF-PCA均较治疗前明显降低(P<0.01),观察组较治疗组降低更明显(P<0.05)。治疗期间两组均未发生脑及其它脏器出血。结论:奥扎格雷钠联合低分子肝素钙治疗TIA效果良好,且无不良反应。Objective：Through the observation of the ozagrel influence of sodium combined low molecular heparin calcium’s treatment on transient ischemic attack（TIA）to ET-1 and whole blood tissue factor coagulant ac-tivity.Method：108 cases of clinically diagnosed patients with TIA were divided into two groups randomly according to table method.One was ozagrel sodium combined low molecular heparin calcium treatment group （combination group,n=54）,and the other one was low molecular heparin calcium treatment group （treatment group,n=54）. Two groups were given conventional measures such as antihypertensive lipid control blood sugar.At the same time, choosed the healthy physical examination for the same period as the reference （normal control group,n=56）.Plas-ma ET-1 and whole blood TF-PCA level before and after treatment were detected.Results：After ozagrel sodium combined low molecular heparin and low molecular heparin calcium treatment,Combined treatment group’s cure rate and effective rate were 70.37% and 94.44% respectively,while that in the treatment group were 46.30% and 72. 22% respectively.Combined treatment group curative effect is superior to the control group with a significant differ-ence （P〈0.05）.Before the treatment,ET-1 and TF-PCA level in combined treatment group and treatment group were no different,after treatment they were significantly decreased in both two groups（P〈0.01）,the lower in com-bined treatment（P〈0.05）.Conclusion：Ozagrel sodium combined low molecular heparin calcium can achieve a good＆amp;nbsp;result on treating TIA without any side effects.

关 键 词：短暂性脑缺血发作 奥扎格雷钠 低分子肝素钙 内皮素-1 组织因子促凝活性 

分 类 号：R563.5[医药卫生—呼吸系统]